FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 499 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,... December 13, 2019 Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and... February 7, 2023 Load more HOT NEWS A Penny for Your Thoughts EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide From smart knives to virtual reality tumours: five innovations in understanding... Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can...
